Novel molecular targets for the therapy of castration-resistant prostate cancer.
about
Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesGonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent mannerProstate cancer invasion and metastasis: insights from mining genomic data.Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.Recent advances in bone-targeted therapies of metastatic prostate cancerIdentification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect ComparisonPrimary melanoma of the prostate: case report and review of the literature.Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.Molecular imaging of prostate cancer: PET radiotracers.Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer.Novel therapies for the treatment of advanced prostate cancer.Targeted α-particle therapy of bone metastases in prostate cancerSrc controls castration recurrence of CWR22 prostate cancer xenografts.Cell mates: paracrine and stromal targets for prostate cancer therapy.Targeting fibroblast growth factor pathways in prostate cancer.Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.Cabozantinib in genitourinary malignancies.The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy.Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.[New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].
P2860
Q26866135-4064036C-93D9-443A-A957-C2CF5403341CQ28537723-82BFB1B0-B02B-41CC-A081-75CE53D6D0F4Q30656758-0CF60876-933E-4F40-9502-C1EB3E2F73E3Q31049104-F90C99DD-BEF8-4DD3-BCAE-2928CC075D68Q33703763-169D1491-25B4-4440-81C8-861695ED38E4Q33716836-B98D1867-0086-4067-A7C5-DFBC676A433BQ34294888-0067F836-BED4-43A9-B186-DAB7AB6552CBQ34412589-DF033A3D-A8EC-4685-8161-1BDE656E2824Q35690088-ACAAC1EA-10B5-4953-8299-28CB77FBB9AAQ35946715-1567512E-7A05-463F-B15A-048844DC1021Q36129937-AB18CB64-0C29-4A47-9E0D-798DEF80F159Q36329301-24359FE0-A81D-41E0-B714-4854F5E11D68Q36665708-F869B174-EF26-4F71-8D6E-60A9E4AFA63CQ37417656-DBC64A21-0E09-41A1-9859-34185E148AF2Q37481145-3BD0986C-91EE-4F25-A6F5-FC798227D064Q38121792-3B1E7CB1-181A-4724-B3B5-F98460EDACE8Q38139831-1B00528D-35BC-42CB-8E58-FFAA3BDCE365Q38152744-96B40CE5-E36F-413D-BD01-313A07C50783Q38438248-D87EA6D0-9FD2-4E82-91B6-4EA33F45D83BQ38795560-55E2C17C-4A22-49C7-96AB-F637EE3B9C0EQ38827251-4641D8D0-5A32-4BF1-8B92-8465789B625FQ38841385-4EB11A05-3CDD-4096-97C0-0929D0F7A280Q39037597-8E1DC301-31BE-45DE-B365-5470C6534F9FQ40239582-61A033D1-88C3-44E5-AC6F-B1E57D00FD1BQ43723219-4ABB27B6-3422-4BCD-A536-C566DD0B0036Q46151487-D283F321-1A7F-4EFA-9E1D-FC5499D5A627Q50672077-2DB07C8D-13B7-40D5-A698-6799500603A2Q54685484-08602FA5-5188-49B5-88A4-58461132C29E
P2860
Novel molecular targets for the therapy of castration-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel molecular targets for the therapy of castration-resistant prostate cancer.
@en
Novel molecular targets for the therapy of castration-resistant prostate cancer.
@nl
type
label
Novel molecular targets for the therapy of castration-resistant prostate cancer.
@en
Novel molecular targets for the therapy of castration-resistant prostate cancer.
@nl
prefLabel
Novel molecular targets for the therapy of castration-resistant prostate cancer.
@en
Novel molecular targets for the therapy of castration-resistant prostate cancer.
@nl
P2093
P1433
P1476
Novel molecular targets for the therapy of castration-resistant prostate cancer.
@en
P2093
Cora N Sternberg
Guru Sonpavde
Neeraj Agarwal
P304
P356
10.1016/J.EURURO.2011.12.028
P407
P577
2011-12-22T00:00:00Z